Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Molinari

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Tumori|July 31, 2014
BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelinesFrancesca Molinari, Stefano Signoroni, Andrea Lampis, et al.
World Journal of Gastroenterology|October 13, 2010
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patientsInti Zlobec, Francesca Molinari, Vittoria Martin, et al.
Oncotarget|June 4, 2021
Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumabSamantha Epistolio, Marco Cefalì, Paolo Spina, et al.
Cancer Biomarkers : Section a of Disease Markers|December 28, 2017
Deregulation of sialidases in human normal and tumor tissuesMatilde Forcella, Alessandra Mozzi, Federico M Stefanini, et al.
Endocrine Pathology|April 25, 2016
Hürthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three CasesMassimo Bongiovanni, Silvia Uccella, Luca Giovanella, et al.
Journal of Clinical Medicine|March 25, 2022
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 ImmunotherapyMarco Cefalì, Samantha Epistolio, Giulia Ramelli, et al.
International Journal of Cancer|February 18, 2010
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancerInti Zlobec, Michal Kovac, Priska Erzberger, et al.
The American Journal of Surgical Pathology|July 13, 2018
Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN)Stefano La Rosa, Silvia Uccella, Francesca Molinari, et al.
Swiss Medical Weekly|September 28, 2023
Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre studyElona Cekani, Carolina Martorell, Francesco Martucci, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 14, 2017
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing miceFrancesca Molinari, Fabrizio Pin, Stefania Gorini, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Tumori|July 31, 2014
BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelinesFrancesca Molinari, Stefano Signoroni, Andrea Lampis, et al.
World Journal of Gastroenterology|October 13, 2010
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patientsInti Zlobec, Francesca Molinari, Vittoria Martin, et al.
Oncotarget|June 4, 2021
Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumabSamantha Epistolio, Marco Cefalì, Paolo Spina, et al.
Cancer Biomarkers : Section a of Disease Markers|December 28, 2017
Deregulation of sialidases in human normal and tumor tissuesMatilde Forcella, Alessandra Mozzi, Federico M Stefanini, et al.
Endocrine Pathology|April 25, 2016
Hürthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three CasesMassimo Bongiovanni, Silvia Uccella, Luca Giovanella, et al.
Journal of Clinical Medicine|March 25, 2022
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 ImmunotherapyMarco Cefalì, Samantha Epistolio, Giulia Ramelli, et al.
International Journal of Cancer|February 18, 2010
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancerInti Zlobec, Michal Kovac, Priska Erzberger, et al.
The American Journal of Surgical Pathology|July 13, 2018
Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN)Stefano La Rosa, Silvia Uccella, Francesca Molinari, et al.
Swiss Medical Weekly|September 28, 2023
Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre studyElona Cekani, Carolina Martorell, Francesco Martucci, et al.
Journal of Cachexia, Sarcopenia and Muscle|November 14, 2017
The mitochondrial metabolic reprogramming agent trimetazidine as an 'exercise mimetic' in cachectic C26-bearing miceFrancesca Molinari, Fabrizio Pin, Stefania Gorini, et al.
Pageof 6